Neal Palejwala, MD
Ophthalmology · Phoenix, AZNPI 1871720755
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 27.5% of the total. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $121.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$9K
- Alimera Sciences, Inc.$6K
- Genentech USA, Inc.$6K
- Ocular Therapeutix, Inc.$3K
- Eyepoint US, Inc.$2K
- Regeneron$1K
- plus $6K from 23 others
Across 285 payments — averaging $2084.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$194K
- Novartis$154K
- Aerie Pharmaceuticals, Inc.$71K
- Genentech, Inc.$63K
- Regeneron$46K
- F. Hoffmann-la Roche AG$34K
- plus $33K from 3 others
What the payments were for
- Consulting fees$7,78523%
- Speaking & faculty fees$9,27728%
- Travel & lodging$1,4584%
- Food & beverage$14,91645%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 63 | $9,182 |
| Alimera Sciences, Inc. | 23 | $6,419 |
| Genentech USA, Inc. | 41 | $5,904 |
| Ocular Therapeutix, Inc. | 8 | $2,673 |
| Eyepoint US, Inc. | 6 | $1,638 |
| Regeneron | 2 | $1,201 |
| Notal Vision, Inc. | 3 | $777 |
| Bausch & Lomb Americas Inc. | 25 | $642 |
| Astellas Pharma US Inc | 15 | $624 |
| AbbVie(2 entities) | 23 | $549 |
| Dutch Ophthalmic, USA | 4 | $472 |
| Genentech, Inc. | 4 | $454 |
| Biogen | 12 | $433 |
| Novartis | 9 | $355 |
| Alcon | 6 | $336 |
| Apellis Pharmaceuticals, Inc. | 9 | $325 |
| ANI Pharmaceuticals, Inc. | 8 | $251 |
| Rxsight Inc | 2 | $239 |
| Carl Zeiss Meditec USA, Inc. | 2 | $201 |
| Eyevance Pharmaceuticals LLC | 1 | $171 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $121 |
| F. Hoffmann-la Roche AG | 1 | $112 |
| Ivantis, Inc | 1 | $109 |
| Dompe US, Inc. | 1 | $95 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Harrow Eye, LLC | 1 | $30 |
| Amgen | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $23 |
| Spark Therapeutics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$7,593
- Iluvien$6,023
- VABYSMO$5,204
- YUTIQ$4,021
- EYP-1901$1,598
- EYLEA$1,224
- SUSVIMO$397
- RXSIGHT CONTACT LENS$239
- RXSIGHT INJECTOR CARTRIDGE$239
- RXSIGHT INJECTOR HANDPIECE$239
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$239
- EVA, combined machine$238
- EVA Ophthalmic Surgical System$233
- Flarex$171
- Izervay$152
- DEXTENZA$147
- Lucentis$128
- OZURDEX$128
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$124
- XIPERE$122
How this compares
$33,449 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 548 | $17,070 |
| Ketorolac Tromethamine | 165 | $3,655 |
| Ofloxacin | 257 | $2,856 |
| Difluprednate | 19 | $1,894 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 52 | $825 |
| Atropine Sulfate | 20 | $748 |
| Brimonidine Tartrate | 120 | $682 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $614 |
| Latanoprost | 55 | $512 |
| MoxifloxacinMoxifloxacin Hcl | 22 | $470 |
| Timolol Maleate | 60 | $384 |
| Acetazolamide | 11 | $384 |
| Ciprofloxacin Hcl | 24 | $321 |
| Prednisone | 21 | $100 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Phoenix
- Pravin DugelPhoenix$176K
- Nishi ShahPhoenix$92K
- Karim JamalPhoenix$72K
- Benjamin HellerPhoenix$41K
- Joshua DuncanPhoenix$30K
- Sachin MehtaPhoenix$23K
- Daniel ChurginPhoenix$15K
- John CasonPhoenix$14K
- Sujit IttyPhoenix$14K
- Elahhe AfkhamnejadPhoenix$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.